Levocetirizine
- Generic Name
- Levocetirizine
- Brand Names
- Xyzal
- Drug Type
- Small Molecule
- Chemical Formula
- C21H25ClN2O3
- CAS Number
- 130018-77-8
- Unique Ingredient Identifier
- 6U5EA9RT2O
- Background
Levocetirizine is a selective histamine H antagonist used to treat a variety of allergic symptoms. It is the R enantiomer of cetirizine. Levocetirizine has greater affinity for the histamine H receptor than cetirizine.
Levocetirizine was granted FDA approval in 1995.
- Indication
Levocetirizine is indicated to treat symptoms of perennial allergic rhinitis and uncomplicated skin manifestations of chronic idiopathic urticaria. It is also used over the counter for a variety of mild allergy symptoms.
- Associated Conditions
- Allergic Rhinitis (AR), Chronic Idiopathic Urticaria, Common Cold, Nasal Congestion, Perennial Allergic Rhinitis (PAR), Seasonal Allergic Rhinitis
- Associated Therapies
- -
A Study Evaluating the Efficacy and Impact on Health-related Quality of Life of Levocetirizine in Adults With Seasonal Allergic Rhinitis
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-02-22
- Last Posted Date
- 2020-07-16
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 596
- Registration Number
- NCT00621959
Safety Study of Levocetirizine Dihydrochloride Oral Liquid Formulation in Children Aged 1 to Less Than 6 Years Suffering From Allergic Rhinitis or Chronic Urticaria of Unknown Origin
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-02-21
- Last Posted Date
- 2015-03-06
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 173
- Registration Number
- NCT00619801
Efficacy of Levocetirizine and Cetirizine in Reducing Symptoms of Seasonal Allergic Rhinitis in Ragweed Sensitive Subjects
Phase 3
Completed
- Conditions
- First Posted Date
- 2007-10-16
- Last Posted Date
- 2013-12-16
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 570
- Registration Number
- NCT00544388
Efficacy and Safety of Levocetirizine and Fexofenadine in Reducing Symptoms of Seasonal Allergic Rhinitis
Phase 4
Completed
- Conditions
- First Posted Date
- 2007-10-11
- Last Posted Date
- 2013-12-12
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 94
- Registration Number
- NCT00542607
Efficacy and Safety of Levocetirizine Versus Loratadine for the Treatment of Perennial Allergic Rhinitis
- First Posted Date
- 2007-09-05
- Last Posted Date
- 2013-12-16
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 71
- Registration Number
- NCT00524836
To Evaluate the Efficacy and Safety of Levocetirizine Versus Loratadine for Treatment of Seasonal Allergic Rhinitis
- First Posted Date
- 2007-09-05
- Last Posted Date
- 2013-12-16
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 67
- Registration Number
- NCT00525278
Study to Compare the Efficacy and Safety Between Levocetirizine and Loratadine for Chronic Idiopathic Urticaria
Phase 3
Completed
- Conditions
- First Posted Date
- 2007-09-05
- Last Posted Date
- 2013-12-12
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 134
- Registration Number
- NCT00525382
Evaluation of Efficacy and Safety of Levocetirizine to Subjects With Perennial Allergic Rhinitis to House Dust Mites
- First Posted Date
- 2007-08-27
- Last Posted Date
- 2013-12-16
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 453
- Registration Number
- NCT00521131
Wheal and Flare Reaction During 24 Hours in Allergic Volunteers.
Phase 1
Completed
- Conditions
- First Posted Date
- 2007-08-27
- Last Posted Date
- 2013-12-16
- Lead Sponsor
- UCB Pharma
- Registration Number
- NCT00521170
Efficacy and Safety of Levocetirizine for Treatment of Recurrent Cough Associated With Other Allergic Symptoms in Children
Phase 2
Completed
- Conditions
- First Posted Date
- 2007-08-27
- Last Posted Date
- 2013-12-12
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 15
- Registration Number
- NCT00520754
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath